Drug Profile
Monoclonal antibody 3S193 - Recepta biopharma
Alternative Names: 3S193; Anti-Lewis Y monoclonal antibody 3S193; hu3S193; Hu3S193 - RECEPTA biopharma; mAb Hu3S193 - Anti-LeY; RebmAb-100Latest Information Update: 07 Sep 2021
Price :
$50
*
At a glance
- Originator Ludwig Institute for Cancer Research
- Developer Recepta biopharma; University of Sao Paulo
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Lewis Y antigen antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Most Recent Events
- 07 Sep 2021 No development reported - Phase-II for Breast cancer (Late-stage disease, Second-line therapy or greater) in Brazil (IV) (NCT01370239)
- 07 Sep 2021 No development reported - Phase-II for Fallopian tube cancer (Second-line therapy or greater) in Brazil (IV) (NCT00617773)
- 07 Sep 2021 No development reported - Phase-II for Ovarian cancer (Second-line therapy or greater) in Brazil (IV) (NCT00617773)